论文部分内容阅读
目的:观察卡培他滨(希罗达)联合顺铂治疗晚期胃癌的疗效及不良反应。方法:采用口服卡培他滨1000mg/m2,每天2次,第1-14天,顺铂30mg/m2,静脉滴注,第1-3天,21天为1周期,连用2周期以后评价疗效。结果:28例晚期胃癌患者均可评价疗效,总有效率RR为53.6%,其中CR2例(7.1%),PR13例(46.4%),SD6例(21.4%),PD7例(25.0%)。不良反应为胃肠道反应Ⅰ-Ⅱ度,手足综合征Ⅰ-Ⅱ度。结论:卡培他滨联合顺铂治疗晚期胃癌近期疗效较好,不良反应较小,患者耐受性高,可改善患者的生存质量。
Objective: To observe the efficacy and adverse reactions of capecitabine (Xeloda) combined with cisplatin in the treatment of advanced gastric cancer. METHODS: Oral capecitabine 1000 mg/m2 was administered twice a day for the first 14 days, cisplatin 30 mg/m2, intravenous drip, the first 1-3 days, 21 days for 1 cycle, and the efficacy was evaluated after 2 consecutive cycles. . Results: 28 cases of advanced gastric cancer patients can evaluate the efficacy of total effective rate of 53.6%, of which CR2 cases (7.1%), PR13 cases (46.4%), SD6 cases (21.4%), PD7 cases (25.0%). Adverse reactions were gastrointestinal reactions I-II degrees, hand-foot syndrome I-II degrees. Conclusion: Capecitabine combined with cisplatin has a good short-term efficacy in the treatment of advanced gastric cancer. The adverse reactions are small, and the patient is well tolerated and can improve the quality of life of patients.